Cue Biopharma, Inc. (CUE)

NASDAQ: CUE · IEX Real-Time Price · USD
2.110
+0.035 (1.69%)
Mar 1, 2024, 4:00 PM EST - Market closed
1.69%
Market Cap 95.21M
Revenue (ttm) 3.82M
Net Income (ttm) -51.89M
Shares Out 45.12M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 202,744
Open 2.120
Previous Close 2.075
Day's Range 2.080 - 2.230
52-Week Range 1.700 - 5.120
Beta 2.14
Analysts Strong Buy
Price Target 10.25 (+385.78%)
Earnings Date Mar 9, 2024

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2018
Employees 51
Stock Exchange NASDAQ
Ticker Symbol CUE
Full Company Profile

Financial Performance

In 2022, Cue Biopharma's revenue was $1.25 million, a decrease of -91.67% compared to the previous year's $14.94 million. Losses were -$53.01 million, 20.0% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price forecast is $10.25, which is an increase of 385.78% from the latest price.

Price Target
$10.25
(385.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate diseas...

3 days ago - GlobeNewsWire

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specif...

3 months ago - GlobeNewsWire

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specif...

4 months ago - GlobeNewsWire

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specif...

4 months ago - GlobeNewsWire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

5 months ago - GlobeNewsWire

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

5 months ago - GlobeNewsWire

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

7 months ago - GlobeNewsWire

Cue Biopharma to Host Investor Call

BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

9 months ago - GlobeNewsWire

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

9 months ago - GlobeNewsWire

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 25, 2023 (GLOBE NEWSWIRE) --  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

10 months ago - GlobeNewsWire

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modula...

10 months ago - GlobeNewsWire

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modula...

10 months ago - GlobeNewsWire

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

11 months ago - GlobeNewsWire

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

1 year ago - GlobeNewsWire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

1 year ago - GlobeNewsWire

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

1 year ago - GlobeNewsWire

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma to Present at Two February 2023 Scientific Conferences

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma Announces Chief Medical Officer Transition

BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) --  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modu...

1 year ago - GlobeNewsWire

Cue Biopharma Reports Third Quarter 2022 Financial Results

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modul...

1 year ago - GlobeNewsWire